Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 1;47(5):690-700.
doi: 10.3899/jrheum.181272. Epub 2019 Aug 1.

Real-world Longterm Effectiveness of Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis Patients from the Rheumatic Diseases Portuguese Register

Elsa Vieira-Sousa  1   2 , Mónica Eusébio  3   4 , Pedro Ávila-Ribeiro  3   4 , Nikita Khmelinskii  3   4 , Rita Cruz-Machado  3   4 , Teresa Martins Rocha  3   4 , Miguel Bernardes  3   4 , Daniela Santos-Faria  3   4 , Joana Leite Silva  3   4 , Helena Santos  3   4 , Cláudia Miguel  3   4 , Pedro Carvalho  3   4 , Tiago Costa  3   4 , Ana Catarina Duarte  3   4 , Tiago Meirinhos  3   4 , Patrícia Nero  3   4 , João Eurico Fonseca  3   4 , Maria José Santos  3   4
Affiliations

Real-world Longterm Effectiveness of Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis Patients from the Rheumatic Diseases Portuguese Register

Elsa Vieira-Sousa et al. J Rheumatol. .

Abstract

Objective: To assess longterm effectiveness of tumor necrosis factor inhibitors (TNFi) in patients with psoriatic arthritis (PsA) registered in the Rheumatic Diseases Portuguese Register, exposed to at least 1 TNFi, prospectively followed between 2001 and 2017.

Methods: Kaplan-Meier analysis was performed for first-, second-, and third-line TNFi. Responses included European League Against Rheumatism (EULAR) criteria, Disease Activity Index for Psoriatic Arthritis (DAPSA), minimal disease activity (MDA), and Ankylosing Spondylitis Disease Activity Score (ASDAS) at 3 and 6 months. Baseline predictors of discontinuation and response were studied using Cox and multivariable multinomial/logistic regression models.

Results: The 750 patients with PsA showed drug retention of 4.1 ± 3.4 years (followup 5.8 ± 3.8 yrs) for first TNFi. Switching to a second (189 patients) or third (50 patients) TNFi further decreased survival by 1.1 years. Female sex, higher baseline 28-joint count Disease Activity Score, and infliximab were predictors of first TNFi discontinuation. After 6 months of the first TNFi, 48.7% of patients achieved a good EULAR criteria response and 20.9% were in DAPSA remission. There were 11.4% in MDA, and 56.4% had a good ASDAS. Responses to the second TNFi were significantly inferior compared to responses to the first TNFi. Female sex and higher baseline Health Assessment Questionnaire-Disability Index were negatively associated with good EULAR response at 3 months, and obesity decreased the chance of response at 6 months.

Conclusion: In this study, switching to a second or third TNFi was associated with significantly lower drug survival and response rates for patients with axial and peripheral PsA subtypes. More successful therapeutic approaches will require considering the effect of sex and obesity on TNFi effectiveness.

Keywords: PSORIATIC ARTHRITIS; REGISTRIES; TUMOR NECROSIS FACTOR INHIBITORS.

PubMed Disclaimer

Publication types

Substances

LinkOut - more resources